Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 6/2022

15.09.2021 | Original Article

Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study

verfasst von: E. Dudinskaya, O. Tkacheva, E. Bazaeva, L. Matchekhina, K. Eruslanova, N. Sharashkina, Yu. Kotovskaya, V. Larina

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the effect of 12 months of treatment with moxonidine or bisoprolol on telomerase activity (TA) and parameters characterizing the arterial wall state in postmenopausal women with arterial hypertension (AH) and osteopenia.

Methods

An open-label randomized study with 114 postmenopausal women with hypertension and osteopenia; pulse wave velocity (PWV), intima-media thickness (IMT), and TA were analyzed initially and after 12 months of therapy with moxonidine (n = 57) or bisoprolol (n = 57).

Results

Both medications effectively lowered blood pressure (BP) in both groups. After 12 months, the moxonidine group showed a significant increase in TA by 45.5% (from 0.87 to 1.15; p < 0.001), in contrast to the bisoprolol group, where TA decreased by 14.1% (from 0.89 to 0.74; p = 0.001). Within 12 months, in the moxonidine group, PWV decreased by 1.9% (from 10.35 ± 2.56 to 10.05 ± 2.29 m/s; p = 0.039), and in the bisoprolol group it increased by 5.8% (from 10.36 ± 2.47 to 11.26 ± 2.60 m/s; p < 0.001). In the moxonidine group, IMT increased by 3.5% on the right and 1.4% on the left, in the bisoprolol group – by 5.7% on the right and 4.2% on the left.

Conclusion

A 12-month treatment with moxonidine but not with bisoprolol in postmenopausal women with AH and osteoporosis was associated with a decrease of arterial stiffness seen as statistically significantly reduced PVW and with increased TA.
Literatur
1.
Zurück zum Zitat McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease. Endocrine. 2004;23:1–10.CrossRefPubMed McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease. Endocrine. 2004;23:1–10.CrossRefPubMed
2.
Zurück zum Zitat Browner WS, Seeley DG, Cummings SR, Vogt TM, Group FTSOOFR. Non-trauma mortality in elderly women with low bone mineral density. Lancet Elsevier. 1991;338:355–8.CrossRef Browner WS, Seeley DG, Cummings SR, Vogt TM, Group FTSOOFR. Non-trauma mortality in elderly women with low bone mineral density. Lancet Elsevier. 1991;338:355–8.CrossRef
3.
Zurück zum Zitat Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke. Am Heart Assoc. 1993;24:940–6. Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke. Am Heart Assoc. 1993;24:940–6.
4.
Zurück zum Zitat Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Lancet. Elsevier. 1999;354:971–5.CrossRef Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Lancet. Elsevier. 1999;354:971–5.CrossRef
5.
Zurück zum Zitat Wiklund P, Nordström A, Jansson J-H, Weinehall L, Nordström P. Low bone mineral density is associated with increased risk for myocardial infarction in men and women. Osteoporos Int. 2012;23:963–70.CrossRefPubMed Wiklund P, Nordström A, Jansson J-H, Weinehall L, Nordström P. Low bone mineral density is associated with increased risk for myocardial infarction in men and women. Osteoporos Int. 2012;23:963–70.CrossRefPubMed
6.
Zurück zum Zitat Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin cases miner bone Metab. CIC Edizioni Int. 2008;5:19–34. Farhat GN, Cauley JA. The link between osteoporosis and cardiovascular disease. Clin cases miner bone Metab. CIC Edizioni Int. 2008;5:19–34.
7.
Zurück zum Zitat Strazhesko ID, Akasheva DU, Dudinskaya EN, Tkacheva ON. Vascular ageing: main features and mechanisms. Cardiovasc Ther Prev. 2012;11(4). Strazhesko ID, Akasheva DU, Dudinskaya EN, Tkacheva ON. Vascular ageing: main features and mechanisms. Cardiovasc Ther Prev. 2012;11(4).
8.
Zurück zum Zitat Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31:1517–26. Nilsson PM, Boutouyrie P, Cunha P, Kotsis V, Narkiewicz K, Parati G, et al. Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013;31:1517–26.
9.
Zurück zum Zitat Fragkiadaki P, et al. Telomere length and telomerase activity in osteoporosis and osteoarthritis (review). Exp Ther Med. 2020;19:1626–32.PubMed Fragkiadaki P, et al. Telomere length and telomerase activity in osteoporosis and osteoarthritis (review). Exp Ther Med. 2020;19:1626–32.PubMed
11.
Zurück zum Zitat Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–8.CrossRefPubMed Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12:1133–8.CrossRefPubMed
12.
Zurück zum Zitat Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001; 12:602 LP–605. Strojek K, Grzeszczak W, Gorska J, Leschinger MI, Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol. 2001; 12:602 LP–605.
13.
Zurück zum Zitat Krespi P, et al. Moxonidine effect on microalbuminuria, trombomodulin, and plasminogen activator ingibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther. 1998;12:463–7. Krespi P, et al. Moxonidine effect on microalbuminuria, trombomodulin, and plasminogen activator ingibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther. 1998;12:463–7.
14.
Zurück zum Zitat Waters J, et al. Use of moxonidine as unitial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (trial of Physiotens in combination) study. J Clin Basic Cardiol. 1999;2:219–24. Waters J, et al. Use of moxonidine as unitial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (trial of Physiotens in combination) study. J Clin Basic Cardiol. 1999;2:219–24.
15.
Zurück zum Zitat Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18:669–75.CrossRefPubMed Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18:669–75.CrossRefPubMed
16.
Zurück zum Zitat Podzolkov V, et al. Moxonidine in combined therapy of metabolic syndrome. Arte Hypertens. 2008;https://doi.org/10.18705/1607-419X-2007-13-4-246-249. Podzolkov V, et al. Moxonidine in combined therapy of metabolic syndrome. Arte Hypertens. 2008;https://​doi.​org/​10.​18705/​1607-419X-2007-13-4-246-249.​
17.
Zurück zum Zitat Rapelli A. Hypertension and obesity in menopause. J Hypertens. 2002;20:S26–8. Rapelli A. Hypertension and obesity in menopause. J Hypertens. 2002;20:S26–8.
19.
Zurück zum Zitat Channaraya V, Marya RK, Somasundaram M, Mitra D, Tibrewala KD. Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open. 2012;2(3):e000683. Channaraya V, Marya RK, Somasundaram M, Mitra D, Tibrewala KD. Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study. BMJ Open. 2012;2(3):e000683.
20.
Zurück zum Zitat Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20:187–91.CrossRefPubMed Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20:187–91.CrossRefPubMed
21.
Zurück zum Zitat Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–104.CrossRefPubMed Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–104.CrossRefPubMed
22.
Zurück zum Zitat Dudinskaya E, Tkacheva O, Bazaeva E. Etc. new opportunities of using moxonidin for control of blood pressure in patients with osteoporosis. Kardiologia. 2018;S7:36–45.CrossRef Dudinskaya E, Tkacheva O, Bazaeva E. Etc. new opportunities of using moxonidin for control of blood pressure in patients with osteoporosis. Kardiologia. 2018;S7:36–45.CrossRef
23.
Zurück zum Zitat Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.CrossRefPubMed Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.CrossRefPubMed
24.
Zurück zum Zitat Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445–8. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445–8.
25.
Zurück zum Zitat Nilsson P, et al. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54:3–10.CrossRefPubMed Nilsson P, et al. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54:3–10.CrossRefPubMed
26.
Zurück zum Zitat Jockel-Schneider Y, Harks I, Haubitz I, Fickl S, Eigenthaler M, Schlagenhauf U, et al. Arterial stiffness and pulse wave reflection are increased in patients suffering from severe periodontitis. PLoS One. Public Libr Sci; 2014;9:e103449. Jockel-Schneider Y, Harks I, Haubitz I, Fickl S, Eigenthaler M, Schlagenhauf U, et al. Arterial stiffness and pulse wave reflection are increased in patients suffering from severe periodontitis. PLoS One. Public Libr Sci; 2014;9:e103449.
29.
Zurück zum Zitat Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest Am Soc Clin Invest. 2017;127:1–4.CrossRef Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest Am Soc Clin Invest. 2017;127:1–4.CrossRef
30.
Zurück zum Zitat Webb DR, Khunti K, Silverman R, Gray LJ, Srinivasan B, Lacy PS, et al. Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia. 2010;53:1190–8. Webb DR, Khunti K, Silverman R, Gray LJ, Srinivasan B, Lacy PS, et al. Impact of metabolic indices on central artery stiffness: independent association of insulin resistance and glucose with aortic pulse wave velocity. Diabetologia. 2010;53:1190–8.
31.
Zurück zum Zitat Friedman J, Ishizuka T, Liu S, Farrell C, Koletsky R, Bedol D, et al. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press Suppl. 1998;3:32–9.PubMed Friedman J, Ishizuka T, Liu S, Farrell C, Koletsky R, Bedol D, et al. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press Suppl. 1998;3:32–9.PubMed
32.
Zurück zum Zitat Ernsberger P, Friedman J, Koletsky R. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens Suppl.1997;15:S9–23. Available from: /pmc/articles/PMC1351308/. Ernsberger P, Friedman J, Koletsky R. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens Suppl.1997;15:S9–23. Available from: /pmc/articles/PMC1351308/.
33.
Zurück zum Zitat Ebinç H, Ozkurt ZN, Ebinç FA, Ucardag D, Caglayan O, Yilmaz M. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res [Internet]. Cambridge Medical Publications; 2008 [cited 2021 May 4];36:80–7. Available from: https://pubmed.ncbi.nlm.nih.gov/18230271/ Ebinç H, Ozkurt ZN, Ebinç FA, Ucardag D, Caglayan O, Yilmaz M. Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res [Internet]. Cambridge Medical Publications; 2008 [cited 2021 May 4];36:80–7. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​18230271/​
35.
Zurück zum Zitat Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274–83. Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274–83.
36.
Zurück zum Zitat Aix E, Gallinat A, Flores I. Telomeres and telomerase in heart regeneration. Differentiation. 2018;100:26–30.CrossRefPubMed Aix E, Gallinat A, Flores I. Telomeres and telomerase in heart regeneration. Differentiation. 2018;100:26–30.CrossRefPubMed
37.
Zurück zum Zitat Serrano AL, Andrés V. Telomeres and cardiovascular disease. Circ Res Am Heart Association. 2004;94:575–84. Serrano AL, Andrés V. Telomeres and cardiovascular disease. Circ Res Am Heart Association. 2004;94:575–84.
38.
Zurück zum Zitat Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis. Circ Res. Am Heart Association. 2006;99:156–64. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis. Circ Res. Am Heart Association. 2006;99:156–64.
39.
Zurück zum Zitat Xin F, Lining W, Yao L. Change of telomere length in angiotensin ii-induced human glomerular mesangial cell senescence and the protective role of losartan. Mol Med Rep. 2011;4:255–60. Xin F, Lining W, Yao L. Change of telomere length in angiotensin ii-induced human glomerular mesangial cell senescence and the protective role of losartan. Mol Med Rep. 2011;4:255–60.
40.
Zurück zum Zitat Le Brigand L, Virsolvy A, Peyrollier K, Manechez D, Godfroid JJ, Guardiola-Lemaître B, et al. Stimulation of insulin release from the MIN6 cell line by a new imidazoline compound, S-21663: evidence for the existence of a novel imidazoline site in β cells. Br J Pharmacol. 1997;122:786–91. https://doi.org/10.1038/sj.bjp.0701449. Le Brigand L, Virsolvy A, Peyrollier K, Manechez D, Godfroid JJ, Guardiola-Lemaître B, et al. Stimulation of insulin release from the MIN6 cell line by a new imidazoline compound, S-21663: evidence for the existence of a novel imidazoline site in β cells. Br J Pharmacol. 1997;122:786–91. https://​doi.​org/​10.​1038/​sj.​bjp.​0701449.​
41.
Zurück zum Zitat Efanov AM, Zaitsev SV, Mest HJ, Raap A, Appelskog IB, Larsson O, et al. The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. Diabetes. 2001;50:797–802. Available from: https://pubmed.ncbi.nlm.nih.gov/11289044/ Efanov AM, Zaitsev SV, Mest HJ, Raap A, Appelskog IB, Larsson O, et al. The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic β-cells in the absence of modulation of KATP channel activity. Diabetes. 2001;50:797–802. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​11289044/​
42.
Zurück zum Zitat Olsen HL, Nørby PL, Høy M, Spee P, Thams P, Capito K, et al. Imidazoline NNC77–0074 stimulates Ca2+−evoked exocytosis in INS-1E cells by a phospholipase A2-dependent mechanism. Biochem Biophys Res Commun. 2003;303:1148–51. Available from: https://pubmed.ncbi.nlm.nih.gov/12684056/ Olsen HL, Nørby PL, Høy M, Spee P, Thams P, Capito K, et al. Imidazoline NNC77–0074 stimulates Ca2+−evoked exocytosis in INS-1E cells by a phospholipase A2-dependent mechanism. Biochem Biophys Res Commun. 2003;303:1148–51. Available from: https://​pubmed.​ncbi.​nlm.​nih.​gov/​12684056/​
44.
Zurück zum Zitat Tesfai J, Crane, L, Mouysset GB. Novel I1-Imidazoline agonist S43126 augment insulin secretion in Min6 cells. J Diabetes Metab. 2012;3:183. Tesfai J, Crane, L, Mouysset GB. Novel I1-Imidazoline agonist S43126 augment insulin secretion in Min6 cells. J Diabetes Metab. 2012;3:183.
46.
Zurück zum Zitat Coluzzi E, Leone S, Sgura A. Oxidative stress induces telomere dysfunction and senescence by replication fork arrest. Cells. 2019;8:19. https://doi.org/10.3390/cells8010019. Coluzzi E, Leone S, Sgura A. Oxidative stress induces telomere dysfunction and senescence by replication fork arrest. Cells. 2019;8:19. https://​doi.​org/​10.​3390/​cells8010019.​
47.
Zurück zum Zitat Mangge H, Herrmann M, Almer G, Zelzer S, Moeller R, Horejsi R, et al. Telomere shortening associates with elevated insulin and nuchal fat accumulation. Sci Rep. 2020;10:1–9. Mangge H, Herrmann M, Almer G, Zelzer S, Moeller R, Horejsi R, et al. Telomere shortening associates with elevated insulin and nuchal fat accumulation. Sci Rep. 2020;10:1–9.
48.
Zurück zum Zitat De Zegher F, Díaz M, Ibáñez L. Association between long telomere length and insulin sensitization in adolescent girls with hyperinsulinemic androgen excess. JAMA Pediatr. 2015;169:787–8. https://jamanetwork.com/ De Zegher F, Díaz M, Ibáñez L. Association between long telomere length and insulin sensitization in adolescent girls with hyperinsulinemic androgen excess. JAMA Pediatr. 2015;169:787–8. https://​jamanetwork.​com/​
49.
Zurück zum Zitat Jose SS, Bendickova K, Kepak T, Krenova Z, Fric J. Chronic inflammation in immune aging: Role of pattern recognition receptor crosstalk with the telomere complex?. Front Immunol. 2017;8:1078. Jose SS, Bendickova K, Kepak T, Krenova Z, Fric J. Chronic inflammation in immune aging: Role of pattern recognition receptor crosstalk with the telomere complex?. Front Immunol. 2017;8:1078.
Metadaten
Titel
Influence of Moxonidine and Bisoprolol on Morphofunctional Condition of Arterial Wall and Telomerase Activity in Postmenopausal Women with Arterial Hypertension and Osteopenia. The Results from a Moscow Randomized Study
verfasst von
E. Dudinskaya
O. Tkacheva
E. Bazaeva
L. Matchekhina
K. Eruslanova
N. Sharashkina
Yu. Kotovskaya
V. Larina
Publikationsdatum
15.09.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2022
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07235-6

Weitere Artikel der Ausgabe 6/2022

Cardiovascular Drugs and Therapy 6/2022 Zur Ausgabe

So beeinflussen Herzinfarkte auf lange Sicht die Sterblichkeit

20.06.2024 ST-Hebungsinfarkt Nachrichten

Wie hoch ist bei Patienten, die nach einem ST-Hebungs-Myokardinfarkt die initiale Hochrisikophase überleben, auf lange Sicht das Sterberisiko? Eine Studie aus Dänemark liefert dazu nun aufschlussreiche Daten.

Protonenpumpenhemmer stoppt Arrhythmie

20.06.2024 Protonenpumpenhemmstoffe Nachrichten

Wenn Nervenfasern aus dem Magen und dem Herzen im Gehirn dicht beieinander liegen, kann auch mal etwas schiefgehen: So lässt sich erklären, weshalb Schmerzen durch einen Magentumor bei einem Mann eine ventrikuläre Extrasystolie auslösen – und PPI diese beenden.

Ob Apixaban nützt oder schadet, entscheidet der CHA2DS2-VASc-Score

20.06.2024 Therapie des Vorhofflimmerns Nachrichten

Patienten mit subklinischem Vorhofflimmern tragen ein erhöhtes Risiko für Schlaganfälle. Da stellt sich die Frage nach einer medikamentösen Antikoagulation. Offenbar hängt es aber vom CHA2DS2-VASc-Score ab, ob die Gabe von Apixaban von Vorteil ist.

Wie SGLT2-Hemmer es schaffen, die Mortalität zu reduzieren

20.06.2024 Kardiologische Therapie Nachrichten

SGLT2-Hemmer verhindern keine Herzinfarkte oder Schlaganfälle. Aber sie reduzieren die kardiovaskuläre Mortalität bei einem breiten Spektrum von Patienten. Wie sie das schaffen, verdeutlicht eine Metaanalyse von Daten aus elf randomisierten Studien.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.